JNJ Oct 2024 140.000 put
| Previous close | 1.6900 |
| Open | 1.6500 |
| Bid | 1.4000 |
| Ask | 1.4700 |
| Strike | 140.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.4400 - 1.5300 |
| Contract range | N/A |
| Volume | |
| Open interest | 483 |
ZacksJ&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
BenzingaJohnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment. Proteologix’s portfolio includes: PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma. PX130, a bispecific antibody t
ZacksJohnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
